CHEMOTHERAPY OF ADVANCED BREAST-CANCER - OUTCOME AND PROGNOSTIC FACTORS
CHEMOTHERAPY OF ADVANCED BREAST-CANCER - OUTCOME AND PROGNOSTIC FACTORS
复制标题
DOI：
10.1038/bjc.1993.467
复制
发表时间：
1993-11-01
影响因子：
8.8
通讯作者：
RUBENS, RD
中科院分区：
文献类型：
--
作者：
GREGORY, WM;SMITH, P;RUBENS, RD
758例连续接受一种或多种化疗方案治疗复发性或转移性乳腺癌的患者的结局。一线治疗后的缓解率为34%。中位缓解持续时间为7.8个月，中位进展时间为3.7个月，中位生存期为7.9个月。在就诊时和开始化疗时记录的因素中，预测缓解的唯一因素是使用蒽环类药物方案，尽管这可能反映了患者选择政策。初始无病间期、肝转移的存在和蒽环类药物的使用与疾病进展时间显著相关。有几个因素与首次化疗后的生存率有关，但蒽环类药物的使用仅显示出非常弱的相关性。缓解mte（16%）和中位至进展时间（2.3个月）显著差于一线治疗。三线化疗后的结果与二线治疗后观察到的结果非常相似。一线化疗达到客观缓解可预测第二次缓解，但把握度不足以用于选择患者进行后续化疗。一线化疗后的至疾病进展时间对二线治疗后的至疾病进展时间无影响。
The outcome for 758 consecutive patients who had received one or mom chemotherapy regimens for recurrent or metastatic breast cancer is presented. The response rate following first line treatment was 34%. Median duration of response was 7.8 months, median time to progression was 3.7 months and median survival was 7.9 months. The only factor predicting for response, of factors recorded at presentation and at initiation of chemotherapy, was the use of anthracycline based regimens, though this may reflect the patient selection policy. Initial disease free interval, presence of liver metastases and use of anthracyclines were significantly related to time to progression. Several factors related to survival following first chemotherapy, but anthracycline usage showed only a very weak correlation.One third of patients (249/758) received two or more chemotherapy regimens. The response mte (16%) and median time to progression (2.3 months) were significantly worse than for first line treatment. The outcome after third line chemotherapy was very similar to that observed following second line treatment. Achievement of an objective response with first line chemotherapy predicted for second response, but with insufficient power to be of use in selecting patients for subsequent chemotherapy. Time to progression following first line chemotherapy did not influence that after second line treatment.